Alliances
The mobile app, dubbed Brisa, has been designed to help patients record their disease progression regardless of condition and treatment plans.
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
Bolt Biotherapeutics was anything but quiet this summer.
The drug, called RGX-314, is a possible one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
Selecta and Cyrus’ partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.
The collaboration between Spark and NeuExcell increased the hope for Huntington’s disease cure in near future. This is going to be a great relief for all the patients.
PRESS RELEASES